(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 April 2014 - Actelion Ltd (SIX: ATLN) today announced financial results for the first three months of 2014. OPERATING HIGHLIGHTS Opsumit - Strong launch momentum in US, Germany, and Switzerland Tracleer - Solid volume growth in non-Opsumit markets Selexipag in PAH - Morbidity/Mortality Phase III topline results expected Q2 2014 Cadazolid - FDA grants Qualified Infectious Disease Product (QIDP) designation FINANCIAL HIGHLIGHTS Product sales of CHF 469 million, up 13% at Constant Exchange Rates (CER), 9% excluding US rebate reversals Core earnings of CHF 189 million, up 19% at CER, 9% excluding US rebate reversals Core EPS of CHF...
↧